Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Henry B Koon

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
The Journal of Clinical Investigation|October 17, 2003
Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFRHongbing Zhang, Gregor Cicchetti, Hiroaki Onda, et al.
Journal of the American Academy of Dermatology|May 13, 2014
Update on primary mucosal melanomaJoselin D Tacastacas, Julie Bray, Yoon K Cohen, et al.
The Journal of Infectious Diseases|February 24, 2012
CpG methylation as a tool to characterize cell-free Kaposi sarcoma herpesvirus DNAMeir Shamay, Nicholas Hand, M Victor Lemas, et al.
Immunity|November 15, 2003
BTK regulates PtdIns-4,5-P2 synthesis: importance for calcium signaling and PI3K activityKan Saito, Kimberley F Tolias, Abdelhafid Saci, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 12, 2010
Phase II AIDS Malignancy Consortium trial of topical halofuginone in AIDS-related Kaposi sarcomaHenry B Koon, Barbara Fingleton, Jeannette Y Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2014
Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS Malignancy Consortium Protocol 042Henry B Koon, Susan E Krown, Jeannette Y Lee, et al.
Future Oncology (London, England)|July 30, 2020
Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study designNikhil I Khushalani, Adi Diab, Paolo A Ascierto, et al.
Journal for Immunotherapy of Cancer|August 18, 2016
Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanomaAsim Amin, David H Lawson, April K S Salama, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2004
Imatinib-induced regression of AIDS-related Kaposi's sarcomaHenry B Koon, Glenn J Bubley, Liron Pantanowitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancerHans J van der Vliet, Hans J J van der Vliet, Henry B Koon, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
The Journal of Clinical Investigation|October 17, 2003
Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFRHongbing Zhang, Gregor Cicchetti, Hiroaki Onda, et al.
Journal of the American Academy of Dermatology|May 13, 2014
Update on primary mucosal melanomaJoselin D Tacastacas, Julie Bray, Yoon K Cohen, et al.
The Journal of Infectious Diseases|February 24, 2012
CpG methylation as a tool to characterize cell-free Kaposi sarcoma herpesvirus DNAMeir Shamay, Nicholas Hand, M Victor Lemas, et al.
Immunity|November 15, 2003
BTK regulates PtdIns-4,5-P2 synthesis: importance for calcium signaling and PI3K activityKan Saito, Kimberley F Tolias, Abdelhafid Saci, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 12, 2010
Phase II AIDS Malignancy Consortium trial of topical halofuginone in AIDS-related Kaposi sarcomaHenry B Koon, Barbara Fingleton, Jeannette Y Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2014
Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS Malignancy Consortium Protocol 042Henry B Koon, Susan E Krown, Jeannette Y Lee, et al.
Future Oncology (London, England)|July 30, 2020
Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study designNikhil I Khushalani, Adi Diab, Paolo A Ascierto, et al.
Journal for Immunotherapy of Cancer|August 18, 2016
Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanomaAsim Amin, David H Lawson, April K S Salama, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2004
Imatinib-induced regression of AIDS-related Kaposi's sarcomaHenry B Koon, Glenn J Bubley, Liron Pantanowitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancerHans J van der Vliet, Hans J J van der Vliet, Henry B Koon, et al.
Pageof 3